Celyad Oncology Sa · EURONEXT:CYAD
Celyad Oncology Sa — European Hematology Association Virtual Congress 2021
23 slides from Celyad Oncology Sa's conference presentation, Jun 11, 2021
Slide 1: Redefining Allogeneic CAR Ts Using a Non-Gene Edited Approach
European Hematology Association Virtual Congress 2021 Redefining Allogeneic CAR Ts Using a Non-Gene Edited Approach June 11, 2021 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks and uncertainties which might cause ac
Slide 3: EHA 2021 Virtual Webcast – Agenda
EHA 2021 Virtual Webcast – Agenda Topic Discussant Welcome & Introductions Filippo Petti Chief Executive Officer shRNA and CYAD-211 Overview David Gilham, Ph.D. Chief Scientific Officer IMMUNICY-1 Phase 1 Trial – Preliminary Data Sébastien Anguille, M.D. University of Antwerp Final Remarks Charles M
Slide 4: shRNA and CYAD-211 Overview
David Gilham, Ph.D. Chief Scientific Officer shRNA and CYAD-211 Overview
Slide 5: shRNA – Non-gene Editing Technology to Engineer Allogeneic CAR Ts
shRNA – Non-gene Editing Technology to Engineer Allogeneic CAR Ts Short hairpin RNA (shRNA) interferes with the expression of the T Cell Receptor (TCR) through targeting of the CD3ζ subunit
Slide 6: CYAD-211 – shRNA-based Allogeneic CAR T Candidate for r/r MM
CYAD-211 – shRNA-based Allogeneic CAR T Candidate for r/r MM Background on CYAD-211 CYAD-211 is our first allogeneic CAR T candidate using shRNA technology utilizing our All-in-One vector approach CYAD-211 co-expresses: CAR – BCMA specific engager Allogeneic technology – single shRNA targeting CD3ζ
Slide 7: CYAD-211 – Anti-Tumor Activity With No Evidence of GvHD
Anti-BCMA CAR T cells with shRNA targeting CD3ζ component exhibited no signs of TCR activation with anti-tumor activity in preclinical models No demonstrable evidence of GvHD when CYAD-211 was infused in sub-lethally irradiated NSG mice, the gold standard preclinical model of GvHD, confirming effici
Slide 8: shRNA Knocks Down TCR Expression to Undetectable Levels
shRNA Knocks Down TCR Expression to Undetectable Levels CYAD-211 cell bank generated through a single production run using a proportion of a single healthy donor apheresis Efficient knock down of cell surface TCR expression to undetectable levels was confirmed in the final CAR T-cell product candida
Slide 9: shRNA as a Novel Allogeneic Technology for CAR T
shRNA as a Novel Allogeneic Technology for CAR T No evidence of GvHD Initial clinical activity Cell engraftment Keys to establishing proof-of-concept GvHD: Graft-versus-Host Disease.
Slide 10: IMMUNICY-1 Phase 1 Trial – Preliminary Data
Sébastien Anguille, M.D. University of Antwerp IMMUNICY-1 Phase 1 Trial – Preliminary Data
Slide 11: CYAD-211 – IMMUNICY-1 First-in-Human Trial
CYAD-211 – IMMUNICY-1 First-in-Human Trial Open-label, Phase 1 dose-escalation trial in r/r multiple myeloma patients Study Design Treatment Schedule Primary objective: Safety and identification of recommended dose of CYAD-211 Secondary objective: Clinical anti-tumor activity and CYAD-211 cell expan
Slide 12: IMMUNICY-1 – Patient Demographics and Clinical Characteristics
IMMUNICY-1 – Patient Demographics and Clinical Characteristics Six patients enrolled across first two dose levels Three of six patients showed high-risk cytogenetics according to mSMART Four of six patients were refractory to last line of therapy Heavily pre-treated patients: Median prior lines of t
Slide 13: CYAD-211 – Preliminary Data Show Favorable Tolerability Profile
CYAD-211 – Preliminary Data Show Favorable Tolerability Profile No DLTs, no GvHD and no CAR‑T‑cell‑related encephalopathy syndrome (CRES) One cytokine release syndrome (CRS) Grade 1 (fever) reported at dose level 1 CRS onset was at the time of the first PR onset in patient #01 One patient experience
Slide 14: CYAD-211 – Encouraging Initial Clinical Activity in Allogeneic Setting
CYAD-211 – Encouraging Initial Clinical Activity in Allogeneic Setting Two patients achieved partial response (PR) Three additional patients presented with stable disease (SD) Patient bar stopped at the first documented progression of the disease or * when the patient discontinued follow-up on study
Slide 15: CYAD-211 – Positive Cell Kinetic Data
CYAD-211 – Positive Cell Kinetic Data Engraftment was seen in all three patients at dose level 2 at a similar magnitude Duration and depth of lymphodepletion was variable and may explain differences in engraftment for dose level 1 Patient #03 showed a surprisingly high level of engraftment compared
Slide 16: IMMUNICY-1 Preliminary Results – Summary
IMMUNICY-1 Preliminary Results – Summary Favorable tolerability profile for CYAD-211 was observed at the first two dose-levels (30x106 and 100x106) across six patients enrolled Two objective responses in conjunction with the current levels of cell engraftment of CYAD-211 are encouraging at these ini
Slide 17: Final Remarks
Charles Morris, M.D. Chief Medical Officer Final Remarks
Slide 18: Advantages of Non-gene Edited Allogeneic CAR Ts using shRNA
Advantages of Non-gene Edited Allogeneic CAR Ts using shRNA Less potential tolerability issues due to no genome modification Level of gene knockdown can be titrated Ability to knockdown multiple targets simultaneously All-in-One vector approach (single vector for all elements) Minimized cell manipul
Slide 19: CYAD-211 – Closer Look at Cell Engraftment from IMMUNICY-1
CYAD-211 – Closer Look at Cell Engraftment from IMMUNICY-1 Even with relatively modest doses of lymphodepleting chemotherapy, there is evidence of a dose dependent increase in cell engraftment Engraftment of shRNA-based allogeneic CAR Ts could offer potential key differentiation to cells developed u
Slide 20: shRNA as a Novel Allogeneic Technology for CAR T
shRNA as a Novel Allogeneic Technology for CAR T No evidence of GvHD Initial clinical activity Cell engraftment Keys to establishing proof-of-concept after dose level 1 and 2 ü ü ü GvHD: Graft-versus-Host Disease.
Slide 21: Next Steps for CYAD-211 IMMUNICY-1 Trial
Next Steps for CYAD-211 IMMUNICY-1 Trial Enrollment in dose level 3 (300x106 cells per infusion) ongoing Additional data from the dose escalation trial are expected during second half 2021
Slide 22: CYAD-211 IMMUNICY-1 Trial – Key Takeaways
CYAD-211 IMMUNICY-1 Trial – Key Takeaways Safety data, clinical activity and cell kinetic data from IMMUNICY-1 support further development of CYAD-211 Preliminary data support shRNA as a novel allogeneic platform technology to develop future product candidates Additional next-generation shRNA-based
Slide 23: Redefining Allogeneic CAR Ts Using a Non-Gene Edited Approach
European Hematology Association Virtual Congress 2021 Redefining Allogeneic CAR Ts Using a Non-Gene Edited Approach June 11, 2021
Celyad Oncology — European Hematology Association Virtual Congress 2021 on 6ix